Blog
RSS FeedPosted by Michael Wonder on 21 Mar 2020
NICE publishes first rapid COVID-19 guidelines
21 March 2020 - New guidelines cover the management of patients in critical care, the management of patients who are having ...
Posted by Michael Wonder on 18 Mar 2020
Professor Gillian Leng, CBE, appointed as new NICE Chief Executive
18 March 2020 - Gillian has held the post of Deputy Chief Executive at NICE since 2007 and is also currently ...
Posted by Michael Wonder on 17 Mar 2020
NICE publishes its first medtech briefing on artificial intelligence software
17 March 2020 - NICE publishes a Medtech Innovation Briefing on artificial intelligence for analysing CT brain scans. ...
Posted by Michael Wonder on 16 Mar 2020
A systematic review of economic evaluations of advanced therapy medicinal products
10 March 2020 - Advanced therapy medicinal products represent a new category of medicinal products with a potential for transformative improvements ...
Posted by Michael Wonder on 16 Mar 2020
NICE hits Keytruda with ‘no’ for urothelial cancer
12 March 2020 - NICE has published a new final draft guidance recommending against the routine use of Keytruda (pembrolizumab) ...
Posted by Michael Wonder on 16 Mar 2020
MPs back Nebhrajani as NICE’s new chair after vetting meeting
16 March 2020 - Sharmila Nebhrajani has been confirmed as the new chair of NICE after a pre-appointment hearing by ...
Posted by Michael Wonder on 16 Mar 2020
HIV drug PrEP to be available across England
15 March 2020 - PrEP will be routinely available across England as part of the government’s aim to end HIV transmission ...
Posted by Michael Wonder on 15 Mar 2020
Brexit means coronavirus vaccine will be slower to reach the UK
15 March 2020 - And it will cost more here because of the UK pulling out of the European Medicines Agency ...
Posted by Michael Wonder on 12 Mar 2020
Defining the role of the public in Health Technology Assessment (HTA) and HTA-informed decision-making processes
10 March 2020 - The terminology used to describe community participation in health technology assessment is contested and frequently confusing. ...
Posted by Michael Wonder on 12 Mar 2020
Around 10,000 people could benefit from new migraine drug as NICE says it’s cost-effective
12 March 2020 - NICE has today published final draft guidance which recommends fremanezumab (also called Ajovy and made by Teva ...
Posted by Michael Wonder on 10 Mar 2020
HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?
10 March 2020 - For at least two decades, health technology assessment has been considered worldwide the most comprehensive and suitable ...
Posted by Michael Wonder on 09 Mar 2020
NICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthma
9 March 2020 - NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe ...
Posted by Michael Wonder on 07 Mar 2020
Is it time to nationalise the pharmaceutical industry?
4 March 2020 - Drug companies fail to take account of the public interest and relentlessly focus on short term returns, ...
Posted by Michael Wonder on 06 Mar 2020
NICE chair nominee Nebhrajani to face MP scrutiny next week
5 March 2020 - The UK government’s preferred candidate to chair NICE – Sharmila Nebhrajani OBE – is due to ...
Posted by Michael Wonder on 06 Mar 2020
Girl loses High Court battle over NICE review of BioMarin’s phenylketonuria drug
5 March 2020 - An 11-year-old girl with the rare disease phenylketonuria has lost a legal battle in the High ...